Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination

Clin Infect Dis. 2023 Feb 8;76(3):e155-e162. doi: 10.1093/cid/ciac590.

Abstract

Background: Immune dysregulation in individuals with Down syndrome (DS) leads to an increased risk for hospitalization and death due to coronavirus disease 2019 (COVID-19) and may impair the generation of protective immunity after vaccine administration.

Methods: The cellular and humoral responses of 55 individuals with DS who received a complete SARS-CoV-2 vaccination regime at 1 to 3 (visit [V 1]) and 6 (V2) months were characterized.

Results: SARS-CoV-2-reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1 and increased at V2. Likewise, an increase in SARS-CoV-2-specific circulating Tfh (cTfh) cells and CD8+ CXCR5+ PD-1hi lymphocytes was already observed at V1 after vaccine administration. Specific immunoglobulin G (IgG) antibodies against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, although IgG titers decreased significantly between both time points.

Conclusions: Our findings show that DS individuals develop an effective immune response to usual regimes of SARS-CoV-2 vaccination.

Keywords: COVID-19; Down syndrome; SARS-CoV-2; immune system; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral
  • Blood Group Antigens*
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Down Syndrome*
  • Humans
  • Immunity
  • Immunoglobulin G
  • Nijmegen Breakage Syndrome*
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Viral
  • Blood Group Antigens
  • COVID-19 Vaccines
  • Immunoglobulin G
  • spike protein, SARS-CoV-2